Drug intelligence / Profile preview

UB-851

Development stage: Phase 3
Lead developer: UBI
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

UB-851 is a biosimilar drug developed by UBI Pharma. It is a biosimilar version of erythropoietin, a biologic medication primarily used to treat anemia, particularly in patients with chronic kidney disease or those undergoing chemotherapy. Erythropoietin functions as a hormone that stimulates red blood cell production by acting on the erythropoietin receptor in the bone marrow. UB-851 has been submitted for drug inspection registration to the Taiwan Food and Drug Administration (TFDA) as part of its regulatory approval process[5].

Other names: UB-851UB851UB 851

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on UB-851.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UB-851.

Explore the full profile